Shares of Clearside Biomedical CLSD rose after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 85.71% over the past year to ($0.13), which missed the estimate of ($0.10).
Revenue of $34,000 decreased by 99.17% from the same period last year, which missed the estimate of $2,120,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 17, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/zvzzdzfv
Price Action
52-week high: $4.53
52-week low: $1.25
Price action over last quarter: down 25.47%
Company Description
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.